106 related articles for article (PubMed ID: 9823432)
21. Acquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes.
Hao XY; Bergh J; Brodin O; Hellman U; Mannervik B
Carcinogenesis; 1994 Jun; 15(6):1167-73. PubMed ID: 8020151
[TBL] [Abstract][Full Text] [Related]
22. Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine.
Fishel ML; Gamcsik MP; Delaney SM; Zuhowski EG; Maher VM; Karrison T; Moschel RC; Egorin MJ; Dolan ME
Cancer Chemother Pharmacol; 2005 Apr; 55(4):333-342. PubMed ID: 15723259
[TBL] [Abstract][Full Text] [Related]
23. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line.
Singh SV; Xu BH; Jani JP; Emerson EO; Backes MG; Rihn C; Scalamogna D; Stemmler N; Specht S; Blanock K
Int J Cancer; 1995 May; 61(3):431-6. PubMed ID: 7729958
[TBL] [Abstract][Full Text] [Related]
25. Effects of diallyl sulfide and diallyl disulfide on cisplatin-induced changes in glutathione and glutathione-S-transferase activity.
Dwivedi C; Abu-Ghazaleh A; Guenther J
Anticancer Drugs; 1996 Sep; 7(7):792-4. PubMed ID: 8949992
[TBL] [Abstract][Full Text] [Related]
26. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
Lau DH; Lewis AD; Ehsan MN; Sikic BI
Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
[TBL] [Abstract][Full Text] [Related]
27. Relationship of glutathione and glutathione-S-transferase to cisplatin sensitivity in human head and neck squamous carcinoma cell lines.
Yellin SA; Davidson BJ; Pinto JT; Sacks PG; Qiao C; Schantz SP
Cancer Lett; 1994 Oct; 85(2):223-32. PubMed ID: 7954341
[TBL] [Abstract][Full Text] [Related]
28. Intracellular glutathione and cytotoxicity of platinum complexes.
Pendyala L; Creaven PJ; Perez R; Zdanowicz JR; Raghavan D
Cancer Chemother Pharmacol; 1995; 36(4):271-8. PubMed ID: 7628045
[TBL] [Abstract][Full Text] [Related]
29. [A study on the relationship between sensitivity to CDDP and inducibility of metallothionein and glutathione of genitourinary tumors].
Yamagata K; Kondo Y
Nihon Hinyokika Gakkai Zasshi; 1995 Oct; 86(10):1575-82. PubMed ID: 7474609
[TBL] [Abstract][Full Text] [Related]
30. Chemical modulation of chemotherapy resistance in cultured oesophageal carcinoma cells.
Sheehan D; Meade G
Biochem Soc Trans; 2000 Feb; 28(2):27-32. PubMed ID: 10816094
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
32. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
[TBL] [Abstract][Full Text] [Related]
33. Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms.
Zhang K; Chew M; Yang EB; Wong KP; Mack P
Mol Pharmacol; 2001 Apr; 59(4):837-43. PubMed ID: 11259628
[TBL] [Abstract][Full Text] [Related]
34. The characterization of two human cervical carcinoma HeLa sublines resistant to cisplatin.
Osmak M; Eljuga D
Res Exp Med (Berl); 1993; 193(6):389-96. PubMed ID: 8122044
[TBL] [Abstract][Full Text] [Related]
35. Over-expression of metallothionein and drug-resistance in bladder cancer.
Saika T; Tsushima T; Ochi J; Akebi N; Nasu Y; Matsumura Y; Ohmori H
Int J Urol; 1994 Jun; 1(2):135-9. PubMed ID: 7627849
[TBL] [Abstract][Full Text] [Related]
36. Fabrication of Eudragit polymeric nanoparticles using ultrasonic nebulization method for enhanced oral absorption of megestrol acetate.
Seo YD; Jin SE; Kim D; Lee DH; Yang SG
Pharm Dev Technol; 2018 Apr; 23(4):407-413. PubMed ID: 29095656
[TBL] [Abstract][Full Text] [Related]
37. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
Chen G; Waxman DJ
Biochem Pharmacol; 1994 Mar; 47(6):1079-87. PubMed ID: 8147907
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins.
Siegsmund MJ; Marx C; Seemann O; Schummer B; Steidler A; Toktomambetova L; Köhrmann KU; Rassweiler J; Alken P
Urol Res; 1999 Jun; 27(3):157-63. PubMed ID: 10422815
[TBL] [Abstract][Full Text] [Related]
39. Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines.
Caliaro MJ; Vitaux P; Lafon C; Lochon I; Néhmé A; Valette A; Canal P; Bugat R; Jozan S
Br J Cancer; 1997; 75(3):333-40. PubMed ID: 9020476
[TBL] [Abstract][Full Text] [Related]
40. [Modulation of cisplatin cytotoxicity by amphotericin B in six human cell lines of medullary thyroid cancer].
Massart C; Gibassier J; Le Gall F; Raoul ML; Leclech G; Lucas C
Bull Cancer; 1996 Aug; 83(8):619-25. PubMed ID: 8869041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
